Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Obstructive Lung Diseases

  Free Subscription


Articles published in Respir Res

Retrieve available abstracts of 236 articles:
HTML format



Single Articles


    June 2022
  1. LE NPK, do Nascimento AF, Schneberger D, Quach CC, et al
    Deficiency of leukocyte-specific protein 1 (LSP1) alleviates asthmatic inflammation in a mouse model.
    Respir Res. 2022;23:165.
    PubMed     Abstract available


  2. MARIN-OTO M, Sanz-Rubio D, Santamaria-Martos F, Benitez I, et al
    Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoea.
    Respir Res. 2022;23:163.
    PubMed     Abstract available


  3. QIN W, Huang H, Dai Y, Han W, et al
    Proteome analysis of urinary biomarkers in a cigarette smoke-induced COPD rat model.
    Respir Res. 2022;23:156.
    PubMed     Abstract available


  4. LIU P, Wang Y, Zhang N, Zhao X, et al
    Comprehensive identification of RNA transcripts and construction of RNA network in chronic obstructive pulmonary disease.
    Respir Res. 2022;23:154.
    PubMed     Abstract available


  5. LOPEZ-CAMPOS JL, Osaba L, Czischke K, Jardim JR, et al
    Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis.
    Respir Res. 2022;23:152.
    PubMed     Abstract available


  6. SALO PM, Mendy A, Wilkerson J, Molsberry SA, et al
    Serum antioxidant vitamins and respiratory morbidity and mortality: a pooled analysis.
    Respir Res. 2022;23:150.
    PubMed     Abstract available


  7. SCHNEIDER S, Merfort I, Idzko M, Zech A, et al
    Blocking P2X purinoceptor 4 signalling alleviates cigarette smoke induced pulmonary inflammation.
    Respir Res. 2022;23:148.
    PubMed     Abstract available


  8. KIM SY, Lee HJ, Lee JK, Park TY, et al
    Association between oxygen saturation level during bronchoscopy and post-bronchoscopy adverse events: a retrospective cohort study.
    Respir Res. 2022;23:144.
    PubMed     Abstract available


    May 2022
  9. LEE H, Kovacs C, Mattman A, Hollander Z, et al
    The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD.
    Respir Res. 2022;23:141.
    PubMed     Abstract available


  10. XIONG XF, Zhu M, Wu HX, Fan LL, et al
    Immunophenotype in acute exacerbation of chronic obstructive pulmonary disease: a cross-sectional study.
    Respir Res. 2022;23:137.
    PubMed     Abstract available


  11. ALQARNI AA, Brand OJ, Pasini A, Alahmari M, et al
    Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation.
    Respir Res. 2022;23:136.
    PubMed     Abstract available


  12. IHRIE MD, McQuade VL, Womble JT, Hegde A, et al
    Exogenous leptin enhances markers of airway fibrosis in a mouse model of chronic allergic airways disease.
    Respir Res. 2022;23:131.
    PubMed     Abstract available


  13. PINCIKOVA T, Parrot T, Hjelte L, Hogman M, et al
    MAIT cell counts are associated with the risk of hospitalization in COPD.
    Respir Res. 2022;23:127.
    PubMed     Abstract available


  14. JACKSON D, Walum J, Banerjee P, Lewis BW, et al
    Th1 cytokines synergize to change gene expression and promote corticosteroid insensitivity in pediatric airway smooth muscle.
    Respir Res. 2022;23:126.
    PubMed     Abstract available


  15. ZHAN Y, Chen J, Wu J, Gu Y, et al
    Human epididymis protein 4 aggravates airway inflammation and remodeling in chronic obstructive pulmonary disease.
    Respir Res. 2022;23:120.
    PubMed     Abstract available


  16. HUANG K, Li F, Wang X, Yan B, et al
    Clinical and cytokine patterns of uncontrolled asthma with and without comorbid chronic rhinosinusitis: a cross-sectional study.
    Respir Res. 2022;23:119.
    PubMed     Abstract available


  17. LIU Y, Qu HQ, Qu J, Chang X, et al
    Burden of rare coding variants reveals genetic heterogeneity between obese and non-obese asthma patients in the African American population.
    Respir Res. 2022;23:116.
    PubMed     Abstract available


  18. FENG J, Sun L, Sun X, Xu L, et al
    Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013-2017: a nationwide population-based cohort study.
    Respir Res. 2022;23:111.
    PubMed     Abstract available


  19. GALGANI I, Annaratone M, Casula D, Di Maro G, et al
    Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study.
    Respir Res. 2022;23:114.
    PubMed     Abstract available


  20. KIM HS, An CH, Teller D, Moon SJ, et al
    The role of retinoid-related orphan receptor-alpha in cigarette smoke-induced autophagic response.
    Respir Res. 2022;23:110.
    PubMed     Abstract available


  21. MAGNUSSON JM, Ericson P, Tengvall S, Stockfelt M, et al
    Involvement of IL-26 in bronchiolitis obliterans syndrome but not in acute rejection after lung transplantation.
    Respir Res. 2022;23:108.
    PubMed     Abstract available


  22. VOGELMEIER CF, Worth H, Buhl R, Criee CP, et al
    Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.
    Respir Res. 2022;23:109.
    PubMed     Abstract available


    April 2022
  23. YANG T, Cai B, Cao B, Kang J, et al
    Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study.
    Respir Res. 2022;23:106.
    PubMed     Abstract available


  24. HAWTHORNE G, Richardson M, Greening NJ, Esliger D, et al
    A proof of concept for continuous, non-invasive, free-living vital signs monitoring to predict readmission following an acute exacerbation of COPD: a prospective cohort study.
    Respir Res. 2022;23:102.
    PubMed     Abstract available


  25. GHOSH AJ, Hobbs BD, Yun JH, Saferali A, et al
    Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
    Respir Res. 2022;23:97.
    PubMed     Abstract available


  26. GUIOT J, Henket M, Frix AN, Gester F, et al
    Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?
    Respir Res. 2022;23:89.
    PubMed     Abstract available


  27. ZOU J, Sun T, Song X, Liu YM, et al
    Distributions and trends of the global burden of COPD attributable to risk factors by SDI, age, and sex from 1990 to 2019: a systematic analysis of GBD 2019 data.
    Respir Res. 2022;23:90.
    PubMed     Abstract available


  28. LI R, Chen Y, Zhao A, Huang L, et al
    Exploring genetic association of insomnia with allergic disease and asthma: a bidirectional Mendelian randomization study.
    Respir Res. 2022;23:84.
    PubMed     Abstract available


  29. GOMEZ N, James V, Onion D, Fairclough LC, et al
    Extracellular vesicles and chronic obstructive pulmonary disease (COPD): a systematic review.
    Respir Res. 2022;23:82.
    PubMed     Abstract available


  30. KELLY TL, Ward M, Pratt NL, Ramsay E, et al
    The association between exacerbation of chronic obstructive pulmonary disease and timing of paracetamol use: a cohort study in elderly Australians.
    Respir Res. 2022;23:80.
    PubMed     Abstract available


    March 2022
  31. LEE KY, Wu SM, Kou HY, Chen KY, et al
    Association of air pollution exposure with exercise-induced oxygen desaturation in COPD.
    Respir Res. 2022;23:77.
    PubMed     Abstract available


  32. YU C, Huang W, Zhou Z, Liang S, et al
    Short isoform thymic stromal lymphopoietin reduces inflammation and aerobic glycolysis of asthmatic airway epithelium by antagonizing long isoform thymic stromal lymphopoietin.
    Respir Res. 2022;23:75.
    PubMed     Abstract available


  33. LU W, Tian Q, Xu R, Zhong C, et al
    Short-term exposure to ambient air pollution and pneumonia hospital admission among patients with COPD: a time-stratified case-crossover study.
    Respir Res. 2022;23:71.
    PubMed     Abstract available


  34. YU H, Lin Y, Zhong Y, Guo X, et al
    Impaired AT2 to AT1 cell transition in PM2.5-induced mouse model of chronic obstructive pulmonary disease.
    Respir Res. 2022;23:70.
    PubMed     Abstract available


  35. ROHL A, Baek SH, Kachroo P, Morrow JD, et al
    Protein interaction networks provide insight into fetal origins of chronic obstructive pulmonary disease.
    Respir Res. 2022;23:69.
    PubMed     Abstract available


  36. ZHANG XY, Li W, Zhang JR, Li CY, et al
    Roles of sirtuin family members in chronic obstructive pulmonary disease.
    Respir Res. 2022;23:66.
    PubMed     Abstract available


  37. HOFFMANN C, Maglakelidze M, von Schneidemesser E, Witt C, et al
    Asthma and COPD exacerbation in relation to outdoor air pollution in the metropolitan area of Berlin, Germany.
    Respir Res. 2022;23:64.
    PubMed     Abstract available


  38. HSU CW, Suk CW, Hsu YP, Chang JH, et al
    Sphingosine-1-phosphate and CRP as potential combination biomarkers in discrimination of COPD with community-acquired pneumonia and acute exacerbation of COPD.
    Respir Res. 2022;23:63.
    PubMed     Abstract available


  39. BRENNAN M, McDonnell MJ, Harrison MJ, Duignan N, et al
    Antimicrobial therapies for prevention of recurrent acute exacerbations of COPD (AECOPD): beyond the guidelines.
    Respir Res. 2022;23:58.
    PubMed     Abstract available


  40. SHIN SH, Kwon SO, Kim V, Silverman EK, et al
    Association of body mass index and COPD exacerbation among patients with chronic bronchitis.
    Respir Res. 2022;23:52.
    PubMed     Abstract available


  41. HUANG JJ, Yang XQ, Zhuo ZQ, Yuan L, et al
    Clinical characteristics of plastic bronchitis in children: a retrospective analysis of 43 cases.
    Respir Res. 2022;23:51.
    PubMed     Abstract available


  42. WEITOFT M, Kadefors M, Stenberg H, Tufvesson E, et al
    Plasma proteome changes linked to late phase response after inhaled allergen challenge in asthmatics.
    Respir Res. 2022;23:50.
    PubMed     Abstract available


  43. MIRAVITLLES M, Soler-Cataluna JJ, Soriano JB, Garcia-Rio F, et al
    Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study.
    Respir Res. 2022;23:49.
    PubMed     Abstract available


  44. KORN S, Howarth P, Smith SG, Price RG, et al
    Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma.
    Respir Res. 2022;23:45.
    PubMed     Abstract available


  45. BLASKOVIC S, Donati Y, Ruchonnet-Metrailler I, Avila Y, et al
    Early life exposure to nicotine modifies lung gene response after elastase-induced emphysema.
    Respir Res. 2022;23:44.
    PubMed     Abstract available


  46. DE VRIES M, Nwozor KO, Muizer K, Wisman M, et al
    The relation between age and airway epithelial barrier function.
    Respir Res. 2022;23:43.
    PubMed     Abstract available


  47. IRIE H, Ozaki M, Chubachi S, Hegab AE, et al
    Short-term intermittent cigarette smoke exposure enhances alveolar type 2 cell stemness via fatty acid oxidation.
    Respir Res. 2022;23:41.
    PubMed     Abstract available


    February 2022
  48. CHEN Y, Kong D, Fu J, Zhang Y, et al
    Associations between ambient temperature and adult asthma hospitalizations in Beijing, China: a time-stratified case-crossover study.
    Respir Res. 2022;23:38.
    PubMed     Abstract available


  49. MENZELLA F, Bargagli E, Aliani M, Bracciale P, et al
    ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
    Respir Res. 2022;23:36.
    PubMed     Abstract available


  50. KULBACKA-ORTIZ K, Triest FJJ, Franssen FME, Wouters EFM, et al
    Restricted spirometry and cardiometabolic comorbidities: results from the international population based BOLD study.
    Respir Res. 2022;23:34.
    PubMed     Abstract available


  51. SCHAUNAMAN N, Dimasuay KG, Kraft M, Chu HW, et al
    Tollip interaction with STAT3: a novel mechanism to regulate human airway epithelial responses to type 2 cytokines.
    Respir Res. 2022;23:31.
    PubMed     Abstract available


  52. MARQUES A, Souto-Miranda S, Machado A, Oliveira A, et al
    COPD profiles and treatable traits using minimal resources: identification, decision tree and stability over time.
    Respir Res. 2022;23:30.
    PubMed     Abstract available


  53. PARK SW, Lim MN, Kim WJ, Bak SH, et al
    Quantitative assessment the longitudinal changes of pulmonary vascular counts in chronic obstructive pulmonary disease.
    Respir Res. 2022;23:29.
    PubMed     Abstract available


  54. CUI Y, Zhan Z, Ma Y, Huang K, et al
    Clinical and economic burden of comorbid coronary artery disease in patients with acute exacerbation of chronic obstructive pulmonary disease: sex differences in a nationwide cohort study.
    Respir Res. 2022;23:28.
    PubMed     Abstract available


  55. WANG H, Zhong Y, Li N, Yu M, et al
    Transcriptomic analysis and validation reveal the pathogenesis and a novel biomarker of acute exacerbation of chronic obstructive pulmonary disease.
    Respir Res. 2022;23:27.
    PubMed     Abstract available


  56. SINGH D, Wild JM, Saralaya D, Lawson R, et al
    Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.
    Respir Res. 2022;23:26.
    PubMed     Abstract available


    January 2022
  57. WU W, Gao J, Chen D, Chen G, et al
    Epithelial microRNA-30a-3p targets RUNX2/HMGB1 axis to suppress airway eosinophilic inflammation in asthma.
    Respir Res. 2022;23:17.
    PubMed     Abstract available


  58. MELO-DIAS S, Valente C, Andrade L, Marques A, et al
    Saliva as a non-invasive specimen for COPD assessment.
    Respir Res. 2022;23:16.
    PubMed     Abstract available


  59. KOO HK, Hoth KF, Make BJ, Regan EA, et al
    Optimism is associated with respiratory symptoms and functional status in chronic obstructive pulmonary disease.
    Respir Res. 2022;23:19.
    PubMed     Abstract available


  60. KLONT F, Horvatovich P, Bowler RP, van Rikxoort E, et al
    Plasma sRAGE levels strongly associate with centrilobular emphysema assessed by HRCT scans.
    Respir Res. 2022;23:15.
    PubMed     Abstract available


  61. LUTHGEN M, Ruller S, Herzmann C
    Characteristics of the deventilation syndrome in COPD patients treated with non-invasive ventilation: an explorative study.
    Respir Res. 2022;23:13.
    PubMed     Abstract available


  62. HUANG X, Guan W, Xiang B, Wang W, et al
    MUC5B regulates goblet cell differentiation and reduces inflammation in a murine COPD model.
    Respir Res. 2022;23:11.
    PubMed     Abstract available


  63. CHIU YC, Lee SW, Liu CW, Lan TY, et al
    Relationship between gut microbiota and lung function decline in patients with chronic obstructive pulmonary disease: a 1-year follow-up study.
    Respir Res. 2022;23:10.
    PubMed     Abstract available


  64. HO T, Nichols M, Nair G, Radford K, et al
    Iron in airway macrophages and infective exacerbations of chronic obstructive pulmonary disease.
    Respir Res. 2022;23:8.
    PubMed     Abstract available


  65. ZHU Z, Lian X, Su X, Wu W, et al
    Exosomes derived from adipose-derived stem cells alleviate cigarette smoke-induced lung inflammation and injury by inhibiting alveolar macrophages pyroptosis.
    Respir Res. 2022;23:5.
    PubMed     Abstract available


  66. LOMMATZSCH M, Speer T, Herr C, Jorres RA, et al
    IgE is associated with exacerbations and lung function decline in COPD.
    Respir Res. 2022;23:1.
    PubMed     Abstract available


    December 2021
  67. TIAN F, Song W, Wang L, Zeng Q, et al
    NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study.
    Respir Res. 2021;22:321.
    PubMed     Abstract available


  68. MCKENZIE J, Nisha P, Cannon-Bailey S, Cain C, et al
    Overnight variation in tidal expiratory flow limitation in COPD patients and its correction: an observational study.
    Respir Res. 2021;22:319.
    PubMed     Abstract available


  69. HERNANDEZ CORDERO AI, Yang CX, Li X, Milne S, et al
    Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease.
    Respir Res. 2021;22:316.
    PubMed     Abstract available


  70. SKIBBA ME, Xu X, Weiss K, Huisken J, et al
    Role of Secretoglobin(+) (club cell) NFkappaB/RelA-TGFbeta signaling in aero-allergen-induced epithelial plasticity and subepithelial myofibroblast transdifferentiation.
    Respir Res. 2021;22:315.
    PubMed     Abstract available


  71. MASPERO J, Agache IO, Kamei T, Yoshida M, et al
    Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial.
    Respir Res. 2021;22:311.
    PubMed     Abstract available


  72. BURBANK AJ, Schworer SA, Sood A, Almond M, et al
    Airway IL-1beta associates with IL-5 production following dust mite allergen inhalation in humans.
    Respir Res. 2021;22:309.
    PubMed     Abstract available


    November 2021
  73. KOSHY K, Sha J, Bennetts K, Langton D, et al
    Safety of delivering bronchial thermoplasty in two treatment sessions.
    Respir Res. 2021;22:307.
    PubMed     Abstract available


  74. CUI Y, Zhang W, Ma Y, Zhan Z, et al
    Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study.
    Respir Res. 2021;22:301.
    PubMed     Abstract available


  75. JOO DH, Lee KH, Lee CH, Woo J, et al
    Developmental endothelial locus-1 as a potential biomarker for the incidence of acute exacerbation in patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:297.
    PubMed     Abstract available


  76. SCHMIDT J, Martin A, Wenzel C, Weber J, et al
    Control of the expiratory flow in a lung model and in healthy volunteers with an adjustable flow regulator: a combined bench and randomized crossover study.
    Respir Res. 2021;22:292.
    PubMed     Abstract available


  77. SVERRILD A, Leadbetter J, Porsbjerg C
    The use of the mannitol test as an outcome measure in asthma intervention studies: a review and practical recommendations.
    Respir Res. 2021;22:287.
    PubMed     Abstract available


  78. SU X, Chen J, Lin X, Chen X, et al
    FERMT3 mediates cigarette smoke-induced epithelial-mesenchymal transition through Wnt/beta-catenin signaling.
    Respir Res. 2021;22:286.
    PubMed     Abstract available


    October 2021
  79. VOGELMEIER CF, Jones PW, Kerwin EM, Boucot IH, et al
    Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
    Respir Res. 2021;22:279.
    PubMed     Abstract available


  80. HARDING JN, Gross M, Patel V, Potter S, et al
    Association between particulate matter containing EPFRs and neutrophilic asthma through AhR and Th17.
    Respir Res. 2021;22:275.
    PubMed     Abstract available


  81. YOSHIZAKI A, Nagano T, Izumi S, Nishiuma T, et al
    Characteristics of the nocturnal desaturation waveform pattern of SpO2 in COPD patients: an observational study.
    Respir Res. 2021;22:276.
    PubMed     Abstract available


  82. NG J, Pacheco-Rodriguez G, Begley L, Huang YJ, et al
    The lung microbiome in end-stage Lymphangioleiomyomatosis.
    Respir Res. 2021;22:277.
    PubMed     Abstract available


  83. LI N, Dai Z, Wang Z, Deng Z, et al
    Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease.
    Respir Res. 2021;22:274.
    PubMed     Abstract available


  84. CHAPMAN KR, Wise RA, Scirica BM, Bhatt DL, et al
    Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers.
    Respir Res. 2021;22:272.
    PubMed     Abstract available


  85. SHIRAISHI M, Higashimoto Y, Sugiya R, Mizusawa H, et al
    Diaphragmatic excursion is correlated with the improvement in exercise tolerance after pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:271.
    PubMed     Abstract available


  86. TUPPER OD, Ulrik CS
    Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma.
    Respir Res. 2021;22:269.
    PubMed     Abstract available


  87. QIU M, Jiang J, Nian X, Wang Y, et al
    Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
    Respir Res. 2021;22:264.
    PubMed     Abstract available


  88. CARSTENSEN S, Gress C, Erpenbeck VJ, Kazani SD, et al
    Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor.
    Respir Res. 2021;22:262.
    PubMed     Abstract available


  89. USMANI O, Roche N, Wahab E, Israel S, et al
    A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Respir Res. 2021;22:261.
    PubMed     Abstract available


  90. CARL J, Schultz K, Janssens T, von Leupoldt A, et al
    The "can do, do do" concept in individuals with chronic obstructive pulmonary disease: an exploration of psychological mechanisms.
    Respir Res. 2021;22:260.
    PubMed     Abstract available


    September 2021
  91. RYBKA-FRACZEK A, Dabrowska M, Grabczak EM, Bialek-Gosk K, et al
    Does bronchial hyperresponsiveness predict a diagnosis of cough variant asthma in adults with chronic cough: a cohort study.
    Respir Res. 2021;22:252.
    PubMed     Abstract available


  92. PARASARAM V, Wang X, Krisanarungson P, Vyavahare N, et al
    Targeted delivery of pentagalloyl glucose inhibits matrix metalloproteinase activity and preserves elastin in emphysematous lungs.
    Respir Res. 2021;22:249.
    PubMed     Abstract available


  93. KELLERER C, Jorres RA, Schneider A, Alter P, et al
    Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET.
    Respir Res. 2021;22:242.
    PubMed     Abstract available


    August 2021
  94. MITSUNE A, Yamada M, Fujino N, Numakura T, et al
    Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation.
    Respir Res. 2021;22:232.
    PubMed     Abstract available


  95. HUBER MB, Schneider N, Kirsch F, Schwarzkopf L, et al
    Long-term weight gain in obese COPD patients participating in a disease management program: a risk factor for reduced health-related quality of life.
    Respir Res. 2021;22:226.
    PubMed     Abstract available


  96. VOGT S, Leuppi JD, Schuetz P, Mueller B, et al
    Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial.
    Respir Res. 2021;22:227.
    PubMed     Abstract available


  97. ZHANG S, Fan Y, Qin L, Fang X, et al
    IL-1beta augments TGF-beta inducing epithelial-mesenchymal transition of epithelial cells and associates with poor pulmonary function improvement in neutrophilic asthmatics.
    Respir Res. 2021;22:216.
    PubMed     Abstract available


  98. HSU HT, Wu CD, Chung MC, Shen TC, et al
    The effects of traffic-related air pollutants on chronic obstructive pulmonary disease in the community-based general population.
    Respir Res. 2021;22:217.
    PubMed     Abstract available


    July 2021
  99. LONG H, Xu H, Janssens JP, Guo Y, et al
    Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.
    Respir Res. 2021;22:209.
    PubMed     Abstract available


  100. TAKEDA K, Kim SH, Joetham A, Petrache I, et al
    Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema.
    Respir Res. 2021;22:207.
    PubMed     Abstract available


  101. WARREN KJ, Poole JA, Sweeter JM, DeVasure JM, et al
    Neutralization of IL-33 modifies the type 2 and type 3 inflammatory signature of viral induced asthma exacerbation.
    Respir Res. 2021;22:206.
    PubMed     Abstract available


  102. PU X, Liu L, Feng B, Zhang Z, et al
    Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta-analysis.
    Respir Res. 2021;22:201.
    PubMed     Abstract available


  103. O'BEIRNE SL, Salit J, Kaner RJ, Crystal RG, et al
    Up-regulation of ACE2, the SARS-CoV-2 receptor, in asthmatics on maintenance inhaled corticosteroids.
    Respir Res. 2021;22:200.
    PubMed     Abstract available


  104. HARBAUM L, Hennigs JK, Simon M, Oqueka T, et al
    Genetic evidence for a causative effect of airflow obstruction on left ventricular filling: a Mendelian randomisation study.
    Respir Res. 2021;22:199.
    PubMed     Abstract available


  105. VAN DEN BERGE M, De Backer J, Van Holsbeke C, De Backer W, et al
    Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
    Respir Res. 2021;22:191.
    PubMed     Abstract available


  106. ZHU J, Wang F, Feng X, Li B, et al
    Family with sequence similarity 13 member A mediates TGF-beta1-induced EMT in small airway epithelium of patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:192.
    PubMed     Abstract available


    June 2021
  107. PAPAKONSTANTINOU E, Koletsa T, Zhou L, Fang L, et al
    Bronchial thermoplasty in asthma: an exploratory histopathological evaluation in distinct asthma endotypes/phenotypes.
    Respir Res. 2021;22:186.
    PubMed     Abstract available


  108. MURO S, Sugiura H, Darken P, Dorinsky P, et al
    Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
    Respir Res. 2021;22:187.
    PubMed     Abstract available


  109. LEMIERE C, Taille C, Lee JK, Smith SG, et al
    Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Respir Res. 2021;22:184.
    PubMed     Abstract available


  110. KOARAI A, Yamada M, Ichikawa T, Fujino N, et al
    Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis.
    Respir Res. 2021;22:183.
    PubMed     Abstract available


  111. MURO S, Suzuki M, Nakamura S, Wang JR, et al
    Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis.
    Respir Res. 2021;22:180.
    PubMed     Abstract available


  112. MO Y, Ye L, Cai H, Zhu G, et al
    SERPINB10 contributes to asthma by inhibiting the apoptosis of allergenic Th2 cells.
    Respir Res. 2021;22:178.
    PubMed     Abstract available


  113. WARDZYNSKA A, Pawelczyk M, Rywaniak J, Makowska J, et al
    Circulating miRNA expression in asthmatics is age-related and associated with clinical asthma parameters, respiratory function and systemic inflammation.
    Respir Res. 2021;22:177.
    PubMed     Abstract available


  114. GU Y, Ye X, Liu Y, Wang Y, et al
    A risk-predictive model for invasive pulmonary aspergillosis in patients with acute exacerbation of chronic obstructive pulmonary disease.
    Respir Res. 2021;22:176.
    PubMed     Abstract available


  115. GIBSON PG, Prazma CM, Chupp GL, Bradford ES, et al
    Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Respir Res. 2021;22:171.
    PubMed     Abstract available


  116. ANDELID K, Ost K, Andersson A, Mohamed E, et al
    Lung macrophages drive mucus production and steroid-resistant inflammation in chronic bronchitis.
    Respir Res. 2021;22:172.
    PubMed     Abstract available


  117. ABDO M, Uddin M, Goldmann T, Marwitz S, et al
    Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma.
    Respir Res. 2021;22:167.
    PubMed     Abstract available


  118. KUROKAWA A, Kondo M, Arimura K, Ashino S, et al
    Less airway inflammation and goblet cell metaplasia in an IL-33-induced asthma model of leptin-deficient obese mice.
    Respir Res. 2021;22:166.
    PubMed     Abstract available


    May 2021
  119. WATSON A, Oberg L, Angermann B, Spalluto CM, et al
    Dysregulation of COVID-19 related gene expression in the COPD lung.
    Respir Res. 2021;22:164.
    PubMed     Abstract available


  120. PADILLA-GALO A, Garcia-Ruiz AJ, Levy Abitbol RC, Olveira C, et al
    Real-life cost-effectiveness of benralizumab in patients with severe asthma.
    Respir Res. 2021;22:163.
    PubMed     Abstract available


  121. LAMB D, De Sousa D, Quast K, Fundel-Clemens K, et al
    RORgammat inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma.
    Respir Res. 2021;22:158.
    PubMed     Abstract available


  122. PERTZOV B, Ronen M, Rosengarten D, Shitenberg D, et al
    Use of capnography for prediction of obstruction severity in non-intubated COPD and asthma patients.
    Respir Res. 2021;22:154.
    PubMed     Abstract available


  123. SIVAPALAN P, Rutishauser J, Ulrik CS, Leuppi JD, et al
    Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials.
    Respir Res. 2021;22:155.
    PubMed     Abstract available


  124. MORICHIKA D, Taniguchi A, Oda N, Fujii U, et al
    Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in mice.
    Respir Res. 2021;22:150.
    PubMed     Abstract available


  125. ZHENG ZG, Sun WZ, Hu JY, Jie ZJ, et al
    Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial.
    Respir Res. 2021;22:149.
    PubMed     Abstract available


  126. JACOBSEN PA, van 't Hul AJ, Djamin RS, Antons JC, et al
    Characteristics and treatable traits of patients with chronic obstructive pulmonary disease (COPD) with and without paid employment.
    Respir Res. 2021;22:147.
    PubMed     Abstract available


  127. LIU MC, Chipps B, Munoz X, Devouassoux G, et al
    Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Respir Res. 2021;22:144.
    PubMed     Abstract available


  128. WEISS DJ, Segal K, Casaburi R, Hayes J, et al
    Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels.
    Respir Res. 2021;22:142.
    PubMed     Abstract available


  129. WANG T, Zhou Y, Kong N, Zhang J, et al
    Weight gain from early to middle adulthood increases the risk of incident asthma later in life in the United States: a retrospective cohort study.
    Respir Res. 2021;22:139.
    PubMed     Abstract available


  130. RAHERISON-SEMJEN C, Parrat E, Nocent-Eijnani C, Mangiapan G, et al
    FASE-CPHG Study: identification of asthma phenotypes in the French Severe Asthma Study using cluster analysis.
    Respir Res. 2021;22:136.
    PubMed     Abstract available


  131. GLOECKL R, Schneeberger T, Leitl D, Reinold T, et al
    Whole-body vibration training versus conventional balance training in patients with severe COPD-a randomized, controlled trial.
    Respir Res. 2021;22:138.
    PubMed     Abstract available


    April 2021
  132. HEALY C, Munoz-Wolf N, Strydom J, Faherty L, et al
    Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.
    Respir Res. 2021;22:133.
    PubMed     Abstract available


  133. KWOK WC, Ho JCM, Tam TCC, Ip MSM, et al
    Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications.
    Respir Res. 2021;22:132.
    PubMed     Abstract available


  134. SINGH D, Criner GJ, Dransfield MT, Halpin DMG, et al
    InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
    Respir Res. 2021;22:130.
    PubMed     Abstract available


  135. PRATTE KA, Curtis JL, Kechris K, Couper D, et al
    Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.
    Respir Res. 2021;22:127.
    PubMed     Abstract available


  136. CHEN A, Diaz-Soto MP, Sanmamed MF, Adams T, et al
    Single-cell characterization of a model of poly I:C-stimulated peripheral blood mononuclear cells in severe asthma.
    Respir Res. 2021;22:122.
    PubMed     Abstract available


  137. MAJORSKI DS, Magnet FS, Thilemann S, Schmoor C, et al
    Portable NIV for patients with moderate to severe COPD: two randomized crossover trials.
    Respir Res. 2021;22:123.
    PubMed     Abstract available


  138. ZHANG WZ, Hoffman KL, Schiffer KT, Oromendia C, et al
    Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.
    Respir Res. 2021;22:126.
    PubMed     Abstract available


  139. SINGH R, Belchamber KBR, Fenwick PS, Chana K, et al
    Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD.
    Respir Res. 2021;22:113.
    PubMed     Abstract available


  140. KIM V, Dolliver WR, Nath HP, Grumley SA, et al
    Mucus plugging on computed tomography and chronic bronchitis in chronic obstructive pulmonary disease.
    Respir Res. 2021;22:110.
    PubMed    


  141. WORTH H, Criee CP, Vogelmeier CF, Kardos P, et al
    Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany.
    Respir Res. 2021;22:108.
    PubMed     Abstract available


  142. SADATSAFAVI M, Khakban A, Tavakoli H, Ehteshami-Afshar S, et al
    Trends in oral corticosteroids use in severe asthma: a 14-year population-based study.
    Respir Res. 2021;22:103.
    PubMed     Abstract available


  143. LI X, Noell G, Tabib T, Gregory AD, et al
    Single cell RNA sequencing identifies IGFBP5 and QKI as ciliated epithelial cell genes associated with severe COPD.
    Respir Res. 2021;22:100.
    PubMed     Abstract available


    March 2021
  144. CHUBACHI S, Yamada Y, Yamada M, Yokoyama Y, et al
    Differences in airway lumen area between supine and upright computed tomography in patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:95.
    PubMed     Abstract available


  145. MACHADO FVC, Spruit MA, Groenen MTJ, Houben-Wilke S, et al
    Frequency and functional translation of low muscle mass in overweight and obese patients with COPD.
    Respir Res. 2021;22:93.
    PubMed     Abstract available


  146. PAN K, Lu J, Song Y
    Artesunate ameliorates cigarette smoke-induced airway remodelling via PPAR-gamma/TGF-beta1/Smad2/3 signalling pathway.
    Respir Res. 2021;22:91.
    PubMed     Abstract available


  147. ZHENG J, Baldi S, Zhao L, Li H, et al
    Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Respir Res. 2021;22:90.
    PubMed     Abstract available


  148. VAN ZELST CM, Kasteleyn MJ, van Noort EMJ, Rutten-van Molken MPMH, et al
    The impact of the involvement of a healthcare professional on the usage of an eHealth platform: a retrospective observational COPD study.
    Respir Res. 2021;22:88.
    PubMed     Abstract available


  149. PARK HJ, Kim SR, Kim S, Lee HS, et al
    Influence of government-driven quality assessment program on patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:87.
    PubMed     Abstract available


  150. SERRE J, Tanjeko AT, Mathyssen C, Vanherwegen AS, et al
    Enhanced lung inflammatory response in whole-body compared to nose-only cigarette smoke-exposed mice.
    Respir Res. 2021;22:86.
    PubMed     Abstract available


  151. BLERVAQUE L, Prefaut C, Forthin H, Maffre F, et al
    Efficacy of a long-term pulmonary rehabilitation maintenance program for COPD patients in a real-life setting: a 5-year cohort study.
    Respir Res. 2021;22:79.
    PubMed     Abstract available


  152. CAO Y, Xing Z, Long H, Huang Y, et al
    Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit.
    Respir Res. 2021;22:77.
    PubMed     Abstract available


  153. SHAHANGIAN K, Ngan DA, Chen HHR, Oh Y, et al
    IL-4Ralpha blockade reduces influenza-associated morbidity in a murine model of allergic asthma.
    Respir Res. 2021;22:75.
    PubMed     Abstract available


    February 2021
  154. PEROTIN JM, Polette M, Deslee G, Dormoy V, et al
    CiliOPD: a ciliopathy-associated COPD endotype.
    Respir Res. 2021;22:74.
    PubMed     Abstract available


  155. WU TD, Fawzy A, Kinney GL, Bon J, et al
    Metformin use and respiratory outcomes in asthma-COPD overlap.
    Respir Res. 2021;22:70.
    PubMed     Abstract available


  156. CALMES D, Huynen P, Paulus V, Henket M, et al
    Chronic infection with Chlamydia pneumoniae in asthma: a type-2 low infection related phenotype.
    Respir Res. 2021;22:72.
    PubMed     Abstract available


  157. LI LY, Yan TS, Yang J, Li YQ, et al
    Impulse oscillometry for detection of small airway dysfunction in subjects with chronic respiratory symptoms and preserved pulmonary function.
    Respir Res. 2021;22:68.
    PubMed     Abstract available


  158. MALVISI L, Taddei L, Yarraguntla A, Wilkinson TMA, et al
    Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints.
    Respir Res. 2021;22:67.
    PubMed     Abstract available


  159. GULEA C, Zakeri R, Alderman V, Morgan A, et al
    Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.
    Respir Res. 2021;22:64.
    PubMed     Abstract available


  160. YANG N, Singhera GK, Yan YX, Pieper MP, et al
    Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells.
    Respir Res. 2021;22:65.
    PubMed     Abstract available


  161. BEKAERT S, Rocks N, Vanwinge C, Noel A, et al
    Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11-CCR3 pathway.
    Respir Res. 2021;22:61.
    PubMed     Abstract available


  162. PISON C, Shah PL, Slebos DJ, Ninane V, et al
    Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes.
    Respir Res. 2021;22:62.
    PubMed     Abstract available


  163. SAITO T, Ichikawa T, Numakura T, Yamada M, et al
    PGC-1alpha regulates airway epithelial barrier dysfunction induced by house dust mite.
    Respir Res. 2021;22:63.
    PubMed     Abstract available


  164. CHEN W, Sadatsafavi M, FitzGerald JM, Lynd LD, et al
    Gender modifies the effect of body mass index on lung function decline in mild-to-moderate COPD patients: a pooled analysis.
    Respir Res. 2021;22:59.
    PubMed     Abstract available


  165. CORDOBA-LANUS E, Cazorla-Rivero S, Garcia-Bello MA, Mayato D, et al
    Telomere length dynamics over 10-years and related outcomes in patients with COPD.
    Respir Res. 2021;22:56.
    PubMed     Abstract available


  166. EHTESHAMI-AFSHAR S, Crothers K, Rodwin B, Bade B, et al
    Does pulmonary subspecialty referral from primary care affect the adherence to vaccination recommendations in COPD patients?
    Respir Res. 2021;22:50.
    PubMed     Abstract available


  167. SAVRAN O, Godtfredsen N, Sorensen T, Jensen C, et al
    COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?
    Respir Res. 2021;22:54.
    PubMed     Abstract available


  168. KANG J, Lee JS, Lee SW, Lee JB, et al
    Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials.
    Respir Res. 2021;22:55.
    PubMed     Abstract available


  169. KERMANI NZ, Song WJ, Badi Y, Versi A, et al
    Correction to: Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma.
    Respir Res. 2021;22:47.
    PubMed    


  170. VAN DEN BERG MPM, Nijboer-Brinksma S, Bos IST, van den Berge M, et al
    The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs.
    Respir Res. 2021;22:48.
    PubMed     Abstract available


  171. WANG Y, Liao K, Liu B, Niu C, et al
    GITRL on dendritic cells aggravates house dust mite-induced airway inflammation and airway hyperresponsiveness by modulating CD4(+) T cell differentiation.
    Respir Res. 2021;22:46.
    PubMed     Abstract available


  172. HU Y, Chen Y, Liu S, Jiang F, et al
    Breastfeeding duration modified the effects of neonatal and familial risk factors on childhood asthma and allergy: a population-based study.
    Respir Res. 2021;22:41.
    PubMed     Abstract available


  173. KIM J, Kim B, Bak SH, Oh YM, et al
    A comparative study of chest CT findings regarding the effects of regional dust exposure on patients with COPD living in urban areas and rural areas near cement plants.
    Respir Res. 2021;22:43.
    PubMed     Abstract available


  174. SONG Q, Chen P, Liu XM
    The role of cigarette smoke-induced pulmonary vascular endothelial cell apoptosis in COPD.
    Respir Res. 2021;22:39.
    PubMed     Abstract available


  175. CALLE RUBIO M, Rodriguez Hermosa JL, de Torres JP, Marin JM, et al
    COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort.
    Respir Res. 2021;22:36.
    PubMed     Abstract available


  176. TAKEUCHI H, Hasan SMT, Zaman K, Takanashi S, et al
    Impact of Haemophilus influenzae type b combination vaccination on asthma symptoms and pneumonia in 5-year-old children in rural Bangladesh: a longitudinal study and comparison with a previous cross-sectional study.
    Respir Res. 2021;22:35.
    PubMed     Abstract available


  177. GALDI F, Pedone C, McGee CA, George M, et al
    Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study.
    Respir Res. 2021;22:30.
    PubMed     Abstract available


    January 2021
  178. FENG Z, Wang J, Xie Y, Li J, et al
    Effects of exercise-based pulmonary rehabilitation on adults with asthma: a systematic review and meta-analysis.
    Respir Res. 2021;22:33.
    PubMed     Abstract available


  179. MAGNUSSEN H, Lucas S, Lapperre T, Quint JK, et al
    Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study.
    Respir Res. 2021;22:25.
    PubMed     Abstract available


  180. LAM R, Kwon S, Riggs J, Sunseri M, et al
    Dietary phenotype and advanced glycation end-products predict WTC-obstructive airways disease: a longitudinal observational study.
    Respir Res. 2021;22:19.
    PubMed     Abstract available


  181. SHIRAHATA T, Sato H, Yogi S, Inoue K, et al
    The product of trunk muscle area and density on the CT image is a good indicator of energy expenditure in patients with or at risk for COPD.
    Respir Res. 2021;22:18.
    PubMed     Abstract available


  182. SCHLEICH F, Graff S, Guissard F, Henket M, et al
    Asthma in elderly is characterized by increased sputum neutrophils, lower airway caliber variability and air trapping.
    Respir Res. 2021;22:15.
    PubMed     Abstract available


  183. LEMAIRE F, Audonnet S, Perotin JM, Gaudry P, et al
    The elastin peptide VGVAPG increases CD4(+) T-cell IL-4 production in patients with chronic obstructive pulmonary disease.
    Respir Res. 2021;22:14.
    PubMed     Abstract available


  184. KERMANI NZ, Song WJ, Badi Y, Versi A, et al
    Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma.
    Respir Res. 2021;22:10.
    PubMed     Abstract available


  185. BAGGE K, Sivapalan P, Eklof J, Hertz FB, et al
    Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid-data from 43,636 outpatients.
    Respir Res. 2021;22:11.
    PubMed     Abstract available


  186. MAO X, Liang C, Niu H, Dong F, et al
    Outcomes associated with comorbid diabetes among patients with COPD exacerbation: findings from the ACURE registry.
    Respir Res. 2021;22:7.
    PubMed     Abstract available


    November 2020
  187. ALNAJEM A, Redha A, Alroumi D, Alshammasi A, et al
    Use of electronic cigarettes and secondhand exposure to their aerosols are associated with asthma symptoms among adolescents: a cross-sectional study.
    Respir Res. 2020;21:300.
    PubMed     Abstract available


    October 2020
  188. SINGH D, Virchow JC, Canonica GW, Vele A, et al
    Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
    Respir Res. 2020;21:285.
    PubMed     Abstract available


  189. ABDO M, Watz H, Veith V, Kirsten AM, et al
    Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
    Respir Res. 2020;21:278.
    PubMed     Abstract available


  190. MENZIES-GOW A, Ponnarambil S, Downie J, Bowen K, et al
    DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Respir Res. 2020;21:279.
    PubMed     Abstract available


  191. NEMOTO M, Nei Y, Bartholmai B, Yoshida K, et al
    Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study.
    Respir Res. 2020;21:275.
    PubMed     Abstract available


  192. GROTH EE, Weber M, Bahmer T, Pedersen F, et al
    Exploration of the sputum methylome and omics deconvolution by quadratic programming in molecular profiling of asthma and COPD: the road to sputum omics 2.0.
    Respir Res. 2020;21:274.
    PubMed     Abstract available


  193. MENZIES-GOW A, Wechsler ME, Brightling CE
    Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Respir Res. 2020;21:268.
    PubMed     Abstract available


  194. MENZIES-GOW A, Colice G, Griffiths JM, Almqvist G, et al
    NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.
    Respir Res. 2020;21:266.
    PubMed     Abstract available


  195. WECHSLER ME, Colice G, Griffiths JM, Almqvist G, et al
    SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Respir Res. 2020;21:264.
    PubMed     Abstract available


  196. EMSON C, Diver S, Chachi L, Megally A, et al
    CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.
    Respir Res. 2020;21:265.
    PubMed     Abstract available


    September 2020
  197. MATUSIAK M, Schurch CM
    Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics.
    Respir Res. 2020;21:252.
    PubMed     Abstract available


  198. MILLER D, Vaidya S, Jauernig J, Ethell B, et al
    Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Respir Res. 2020;21:248.
    PubMed     Abstract available


    June 2020
  199. ESTEBAN C, Arostegui I, Aramburu A, Moraza J, et al
    Predictive factors over time of health-related quality of life in COPD patients.
    Respir Res. 2020;21:138.
    PubMed     Abstract available


  200. DAY NC, Kumar S, Criner G, Dransfield M, et al
    Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
    Respir Res. 2020;21:139.
    PubMed     Abstract available


  201. MATHYSSEN C, Aelbrecht C, Serre J, Everaerts S, et al
    Local expression profiles of vitamin D-related genes in airways of COPD patients.
    Respir Res. 2020;21:137.
    PubMed     Abstract available


  202. SINGH D, Criner GJ, Naya I, Jones PW, et al
    Measuring disease activity in COPD: is clinically important deterioration the answer?
    Respir Res. 2020;21:134.
    PubMed     Abstract available


    May 2020
  203. KIM T, Cho HB, Kim WJ, Lee CH, et al
    Quantitative CT-based structural alterations of segmental airways in cement dust-exposed subjects.
    Respir Res. 2020;21:133.
    PubMed     Abstract available


  204. FERGUSON GT, Brown N, Compton C, Corbridge TC, et al
    Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Respir Res. 2020;21:131.
    PubMed     Abstract available


  205. MARTINEZ FJ, Lipworth BJ, Rabe KF, Collier DJ, et al
    Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Respir Res. 2020;21:128.
    PubMed     Abstract available


  206. RAYMAKERS A, Sin DD, Sadatsafavi M, FitzGerald JM, et al
    Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study.
    Respir Res. 2020;21:118.
    PubMed     Abstract available


  207. GREULICH T, Tuffers J, Mager S, Eder A, et al
    High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis.
    Respir Res. 2020;21:106.
    PubMed     Abstract available


  208. WILSON AC, Kumar PL, Lee S, Parker MM, et al
    Heme metabolism genes Downregulated in COPD Cachexia.
    Respir Res. 2020;21:100.
    PubMed     Abstract available


    April 2020
  209. MACKAY AJ, Kostikas K, Roche N, Frent SM, et al
    Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
    Respir Res. 2020;21:93.
    PubMed     Abstract available


  210. SCHERR A, Schumann DM, Karakioulaki M, Franchetti L, et al
    Endothelial dysfunction is not a predictor of outcome in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:90.
    PubMed     Abstract available


  211. DING Y, Yang Y, Li Q, Feng Q, et al
    The correlation between CYP4F2 variants and chronic obstructive pulmonary disease risk in Hainan Han population.
    Respir Res. 2020;21:86.
    PubMed     Abstract available


  212. TUNG LF, Shen SY, Shih HH, Chen YT, et al
    Effect of high-flow nasal therapy during early pulmonary rehabilitation in patients with severe AECOPD: a randomized controlled study.
    Respir Res. 2020;21:84.
    PubMed     Abstract available


    March 2020
  213. LANGTON D, Bennetts K, Noble P, Plummer V, et al
    Bronchial thermoplasty reduces airway resistance.
    Respir Res. 2020;21:76.
    PubMed     Abstract available


  214. ZHENG J, Xu JF, Jenkins M, Assam PN, et al
    Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naive patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.
    Respir Res. 2020;21:69.
    PubMed     Abstract available


  215. GAO S, Chen J, Xie J, Wang J, et al
    The effects of BAFF on T lymphocytes in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:66.
    PubMed     Abstract available


  216. MAGDY DM, Metwally A
    Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic hypercapnic respiratory failure: a randomized trial.
    Respir Res. 2020;21:64.
    PubMed     Abstract available


  217. PASCUAL-GUARDIA S, Ataya M, Ramirez-Martinez I, Yelamos J, et al
    Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients.
    Respir Res. 2020;21:63.
    PubMed     Abstract available


    February 2020
  218. AXSON EL, Ragutheeswaran K, Sundaram V, Bloom CI, et al
    Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis.
    Respir Res. 2020;21:54.
    PubMed     Abstract available


  219. GOORSENBERG AWM, d'Hooghe JNS, Slats AM, van den Aardweg JG, et al
    Resistance of the respiratory system measured with forced oscillation technique (FOT) correlates with bronchial thermoplasty response.
    Respir Res. 2020;21:52.
    PubMed     Abstract available


  220. SALVI SS, Brashier BB, Londhe J, Pyasi K, et al
    Phenotypic comparison between smoking and non-smoking chronic obstructive pulmonary disease.
    Respir Res. 2020;21:50.
    PubMed     Abstract available


  221. XIE M, Liu X, Cao X, Guo M, et al
    Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017.
    Respir Res. 2020;21:49.
    PubMed     Abstract available


  222. SINGH D, Martinez FJ, Watz H, Bengtsson T, et al
    A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD.
    Respir Res. 2020;21:47.
    PubMed     Abstract available


  223. TAM A, Tanabe N, Churg A, Wright JL, et al
    Sex differences in lymphoid follicles in COPD airways.
    Respir Res. 2020;21:46.
    PubMed     Abstract available


  224. PADBERG I, Schneider A, Rohmann JL, Kelley SW, et al
    Impact of COPD and anemia on motor and cognitive performance in the general older population: results from the English longitudinal study of ageing.
    Respir Res. 2020;21:40.
    PubMed     Abstract available


    January 2020
  225. FRATTA PASINI AM, Stranieri C, Ferrari M, Garbin U, et al
    Oxidative stress and Nrf2 expression in peripheral blood mononuclear cells derived from COPD patients: an observational longitudinal study.
    Respir Res. 2020;21:37.
    PubMed     Abstract available


  226. TANNO A, Fujino N, Yamada M, Sugiura H, et al
    Decreased expression of a phagocytic receptor Siglec-1 on alveolar macrophages in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:30.
    PubMed     Abstract available


  227. SIEVI NA, Brack T, Brutsche MH, Frey M, et al
    "Can do, don't do" are not the lazy ones: a longitudinal study on physical functioning in patients with COPD.
    Respir Res. 2020;21:27.
    PubMed     Abstract available


  228. DIVO MJ, DePietro MR, Horton JR, Maguire CA, et al
    Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial.
    Respir Res. 2020;21:26.
    PubMed     Abstract available


  229. KAHNERT K, Fohrenbach M, Lucke T, Alter P, et al
    The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET.
    Respir Res. 2020;21:28.
    PubMed     Abstract available


  230. JIANG JX, Shen HJ, Guan Y, Jia YL, et al
    ZDHXB-101 (3',5-Diallyl-2, 4'-dihydroxy-[1,1'-biphen-yl]-3,5'-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator
    Respir Res. 2020;21:22.
    PubMed     Abstract available


  231. PEREA L, Rodrigo-Troyano A, Canto E, Dominguez-Alvarez M, et al
    Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity.
    Respir Res. 2020;21:21.
    PubMed     Abstract available


  232. LONG GH, Southworth T, Kolsum U, Donaldson GC, et al
    The stability of blood Eosinophils in chronic obstructive pulmonary disease.
    Respir Res. 2020;21:15.
    PubMed     Abstract available


  233. BAFADHEL M, Singh D, Jenkins C, Peterson S, et al
    Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis.
    Respir Res. 2020;21:17.
    PubMed     Abstract available


  234. WALSCHER J, Gross B, Morisset J, Johannson KA, et al
    Comorbidities and survival in patients with chronic hypersensitivity pneumonitis.
    Respir Res. 2020;21:12.
    PubMed     Abstract available


  235. HARTLEY BF, Barnes NC, Lettis S, Compton CH, et al
    Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis.
    Respir Res. 2020;21:5.
    PubMed     Abstract available


  236. HARRIES TH, Rowland V, Corrigan CJ, Marshall IJ, et al
    Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.
    Respir Res. 2020;21:3.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Obstructive Lung Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: